Highlights
-
Thrombophilia screening should be a global, comprehensive, personalized evaluation of the patient’s pro-thrombotic state.
-
Global thrombophilia evaluation is indicated in all patients with thromboembolism, whereas thrombophilia-specific laboratory screening only in selected cases.
-
Thrombophilia investigation should not be performed just for defining the duration of anticoagulation, but it helps in estimating the individual recurrence risk for thrombotic disease, the need for thrombotic prophylaxis or for the decision to prolong anticoagulation therapy.
-
Genetic causes of thrombophilia are significant risk factors for a first thromboembolic event but they do not influence decisively recurrent thrombotic risk.
-
Although single genetic thrombophilia is mostly kept in balance in children and young adults, it can cause serious thrombotic disease in adults, as soon as acquired risk factors are additionally prevalent (gene-environment interaction) or if multiple deviations in thrombophilia genes co-exist (gene-gene interaction).
Introduction
Venous thromboembolism
Provoking risk factors | Non-provoking risk factors | Genetic risk factors |
---|---|---|
Cancer | Age > 60 years | Antithrombin-deficiency |
Surgery | Sex | Antithrombin-resistance |
Trauma | Ethnicity | Protein C deficiency |
Acute infection | Oral contraceptive | Protein S deficiency |
Immobilization | Hormone therapy | Factor V-Leiden (G1691A) |
Pregnancy | BMI | Factor II-Mutation (G20210A) |
Post-partum period | Elevated FVIII level | |
Long distance travel | Dysfibrinogenemia | |
Hospitalization | Blood group Non-O | |
Catheterization | Loci for VTE susceptibility: TSPAN15, SLC44A2 |
Major persistent | Major transient |
---|---|
Male sex | Surgery |
Age > 65 years | Trauma |
Active cancer | Cesarean section |
Myeloproliferative neoplasm | Pregnancy—Puerperium |
Antiphospholipid syndrome | Severe infection |
Behçet disease—Hughes–Stovin syndrome | Nephrotic syndrome |
Cushing syndrome | |
Paroxysmal nocturnal hemoglobinuria (PNH) | |
Klinefelter syndrome | |
Sickle cell disease | |
Some forms of inherited thrombophilia |
Minor persistent | Minor transient |
---|---|
Some forms of inherited thrombophilia | Smoking |
Non-O blood group | Dehydration |
BMI > 30 kg/m2 | Treatment with synthetic estrogens |
Post thrombotic syndrome | Varicosis |
Chronic bowel inflammatory disease | Immobilisation—Flight > 4 h |
Lower extremity paralysis or paresis | Intermittent chemotherapy |
Congestive heart failure | Testosterone therapy |
Depression | |
Lupus anticoagulants | |
Calculated creatinine clearance < 50 mL per minutes |
Inherited thrombophilia
Prevalence in the general population (%) | Prevalence in VTE cohort (%) | Annual VTE Risk (%/y) | |
---|---|---|---|
Antithrombin deficiency | 0.02 | 0.5 | 1.1 |
Protein C deficiency | 0.15 | 6 | 0.7 |
Protein S deficiency | 0.1 | 2 | 0.3 |
FV Leiden heterozygous | 5 | 16 | 0.5 |
FV Leiden homozygous | 0.004 | 0.01 | 1.3 |
FII G20210A heterozygous | 2 | 7 | 0.4 |
FII G20210A homozygous | 0.1 | 2 | 1.1 |
FV Leiden/FII heterozygous | 0.1 | 3 | 0.5 |
Relative Risk | First VTE | Recurrent VTE |
---|---|---|
Factor V Leiden | ||
Heterozygous | 4.9–9.7 | 1.3 |
Homozygous | 40–80 | – |
Factor II-Mutation | 1.9–3.8 | 1.4 |
Antithrombin deficiency | 5–8 | 0.5 |
Protein C deficiency | 5–8 | 2.5 |
Protein S deficiency | 1.7–8 | 2.5 |
Dysfibrinogenemia | – | |
Hyperhomocysteinemia | – | |
Non-O blood type | 2.5 |
Inherited thrombophilia screening in children
Thrombophilia screening in adult patients
Clinical thrombophilia evaluation
Coagulation | Prothrombin time (PT) |
Activated partial thromboplastin time (aPTT) | |
D-Dimer | |
Fibrinogen (functional assay) Factor VIII level | |
Lupus anticoagulants, anti-cardiolipin, anti-β2 glycoprotein I antibodies | |
Hematology | Complete blood count |
Chemistry | Kidney, liver, infection parameters, lactate dehydrogenase (LDH) |
Personalized thrombophilia evaluation
- > 60 years: no genetic thrombophilia screening (Table 7)
- < 50 years: consider if thromboembolism (TE) may be the first cancer manifestation, including hematologic and myeloproliferative neoplasm and PNH
- < 50 years, female patients: consider as well autoimmune disease (i.e. Lupus Anticoagulans, antiphospholipid syndrome, Table 2)
- < 50 years, male, idiopathic: perform genetic thrombophilia screening
- < 40 years: consider illicit drug consumption or therapy (including cocaine, testosterone, erythropoietin)
- < 40 years: if TE idiopathic, in unusual sites or paradoxical perform thrombophilia screening including genetic tests (Table 6)
- < 40 years, female: if TE during pregnancy contraceptive or hormonal replacement or TE before prescribing hormonal replacement or multiple inexplicable pregnancy losses: perform genetic thrombophilia screening (Table 6)
Idiopathic VTE < 50 years |
Young patients with arterial ischemia caused by paradoxical embolism (right-to-left shunt) |
VTE in unusual sites |
Women with VTE during pregnancy or puerperium |
Women with VTE during use of oral contraceptive or hormonal replacement |
Women with VTE before prescribing hormonal replacement |
Women with multiple inexplicable pregnancy losses |
Young women with a strongly positive family history, before prescribing oral contraceptive |
First VTE and a positive family history for VTE |
Young women with a negative personal and familial history, before prescribing oral contraceptive |
Patient with tumor (active or inactive) |
Patient with VTE after surgery and/or trauma |
Patient > 60 years |
Patient > 50 years with 1 or multiple strong risk factors |
Relative 1. or 2. grades with VTE > 60 years |
Patient without descendents or 1st degree relatives |
Thrombophilia screening should not be performed in the acute phase after VTE diagnosis |
Genetic thrombophilia testing
Avoid universal screening
Selected screening
Family screening
Role and consequences of thrombophilia screening:
Regarding thrombotic risk
Regarding therapy of thrombosis
Role of a positive diagnosis of thrombophilia regarding thrombosis prophylaxis
Transient risk factors | |
---|---|
Immobilization | Compression stocking, LMWH prophylaxis, DOACs |
Flight > 4 h | Regular movement during the flight, fluid intake, compression stockings, LMWH, DOACs |
Surgery | Pneumatic and compression stockings, early mobilization, hydration, LMWH, DOACs |
Pregnancy—Puerperium | Compression stockings, hydration, LMWH |
Medication | Avoid estrogens, EPO, testosterone |
Extended varicosis | Evaluation of surgical repair, stockings, LMWH |
Smoking | Avoid or interrupt smoking |
Persistent risk factors | |
---|---|
Myeloproliferative Neoplasm: PV, ET, PMF | Hematocrit and blood cells under therapeutic limits, prophylaxis or anticoagulation |